Ligand News and Research

RSS

Elevated levels of circulating proteins linked with protection against diabetic kidney disease

Elevated levels of three specific circulating proteins are associated with protection against kidney failure in diabetes, according to research from the Joslin Diabetes Center that will be published 30th June in Science Translational Medicine.

30 Jun 2021

LSL60101 compound improves cognitive deficit in murine models with Alzheimer’s

The LSL60101 compound, a specific ligand of the I2-IR receptors in the brain, could shed light on the development of future strategies against Alzheimer's disease.

29 Jun 2021

Nanotechnology and the fight against COVID-19

In a review paper published in the open-access MDPI journal Viruses, a team of researchers explored the potential of nanotechnology to alleviate the current and future coronavirus burden. The team focused on its potential role in the detection, diagnosis, protection, and treatment of SARS-CoV-2 infection.

29 Jun 2021

New insights on how an important class of immune receptors are activated

Scientists from within the Antibody and Vaccine Group at the University of Southampton have gained novel insights into how an important class of immune receptors called tumour necrosis factor receptors (TNFR) are activated.

25 Jun 2021

Targeting lung inflammation with cell membrane-based dexamethasone nanodelivery platform

Recently, researchers discuss their development of cell membrane-based nanoparticles that successfully delivered dexamethasone directly to inflamed lung cells.

21 Jun 2021

Could a fungus-derived compound reduce hyperinflammation in severe COVID-19?

New research from scientists at the University of Pennsylvania, USA, demonstrates that cyclosporine A (CSA), a calcineurin inhibitor that modulates cytokine production, may have potential antiviral properties against coronaviruses.

18 Jun 2021

Using natural killers from the immune system to target breast cancer cells

It sounds like a plot from a Quentin Tarantino movie -- something sets off natural killers and sends them on a killing spree.

16 Jun 2021

Differential localization may explain different physiological functions of receptors

In the heart there are two different subtypes of beta-adrenergic receptors - beta1 and beta2 - which are activated by the stress hormones adrenaline and noradrenaline.

15 Jun 2021

Artificial intelligence for predicting TMB-H colorectal cancer from histopathological characteristics

Biomarkers are important determinants of appropriate and effective therapeutic approaches for various diseases including cancer.

14 Jun 2021

MIT researchers develop a molecular assay to detect sub-picomolar levels of the SARS-CoV-2's receptor-binding domain

A team of researchers at MIT has developed a molecular assay to detect sub-picomolar levels of the SARS-CoV-2’s spike protein receptor-binding domain (S-RBD) using computationally validated peptide beacons in a single-step detection through the production of a fluorescence signal.

8 Jun 2021

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

A team of scientists from the National Institutes of Health (NIH), USA, has recently identified six novel small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. The study is currently available on the bioRxiv* preprint server.

8 Jun 2021

Rice scientist wins NIH grant to model and analyze protein-ligand interactions in cancer research

Computer scientist Lydia Kavraki of Rice University's Brown School of Engineering has won a prestigious National Institutes of Health U01 grant to develop a new approach to model and analyze protein-ligand interactions in cancer research.

7 Jun 2021

New therapeutic approach developed to treat psoriatic arthritis

An international team of researchers, led by UC Davis Health, has developed a new therapeutic approach to treating psoriatic arthritis, a chronic inflammatory disease affecting the joints.

3 Jun 2021

How do common mutations in SARS-CoV-2’s spike affect its binding affinity with host cell receptors?

Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.

21 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

Virtual analysis identifies a potential natural inhibitor of SARS-CoV-2 Nsp15

A new paper reports the discovery of promising antiviral hit compounds through the use of computational modeling studies on natural compounds.

19 May 2021

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

Researchers at St Jude Children’s Research Hospital found that toll-like receptor 2 detects the SARS-CoV-2 envelope protein-producing inflammatory cytokines.

19 May 2021

New class of anti-cancer compounds effectively kills liver and breast cancer cells

A team of Oregon State University scientists has discovered a new class of anti-cancer compounds that effectively kill liver and breast cancer cells.

12 May 2021

SARS-CoV-2 main protease conformations are temperature-dependent

New research led by Daniel A Keedy of City University of New York, USA, shows the structure of the main protease (Mpro) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative pathogen of coronavirus disease 2019 (COVID-19) – reacts to being heated and cooled. The temperature-dependent conformations could act as potential therapeutic targets to neutralize the virus.

9 May 2021

Study reports vitamin C inhibits SARS-CoV-2 virus main protease

Based on structural analysis, researchers found that vitamin C binds to 3CLpro, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease essential in viral replication. In vitro cell inhibition studies also showed vitamin C could inhibit 3CLpro, indicating a possible new antiviral treatment method.

6 May 2021